Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAPENTADOL vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Management of moderate to severe acute pain,Management of neuropathic pain associated with diabetic peripheral neuropathy,Management of chronic pain
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Extensively metabolized via conjugation (primarily glucuronidation) and by CYP2C9 and CYP2C19 to a minor extent. Major metabolites are inactive.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces.
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Approximately 20% bound to plasma proteins (primarily albumin).
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
540 L (approximately 7.7 L/kg for a 70 kg adult), indicating extensive tissue distribution.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Oral: approximately 32% due to first-pass metabolism; intravenous: 100%.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
Creatinine clearance (Cr Cl) 30-80 m L/min: No adjustment needed. Cr Cl <30 m L/min: Not recommended (extended-release) or use with caution and reduce dose by 50% (immediate-release). Hemodialysis: Not recommended.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and increase dosing interval to every 8 hours (immediate-release) or every 12 hours (extended-release). Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Safety and efficacy not established in children <18 years; not recommended.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Start at low end of dosing range; monitor for CNS effects, constipation, and respiratory depression. Immediate-release: 50 mg every 6 hours initially; extended-release: not recommended for opioid-naïve elderly.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; seizures; risk of serotonin syndrome; adrenal insufficiency; and withdrawal.
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days; hypersensitivity to tapentadol.
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
No specific food interactions. Alcohol should be avoided due to additive CNS depressant effects.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use near term due to risk of respiratory depression at birth.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.8). Infant exposure is low but may cause sedation or respiratory depression in neonates, especially with high maternal doses or prolonged use. Caution advised; monitor infant for signs of sedation or poor feeding.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
No specific dose adjustments recommended, but pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require higher doses to maintain analgesia. Use lowest effective dose for shortest duration. Avoid chronic use; consider opioid-sparing strategies.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
Tapentadol is a dual-mechanism opioid agonist and norepinephrine reuptake inhibitor. It has a lower incidence of opioid-induced nausea and vomiting compared to morphine. Avoid use in patients with severe hepatic impairment. Maximum daily dose is 600 mg. Do not crush extended-release tablets. Discontinuation should be gradual to avoid withdrawal. Serotonin syndrome risk when combined with serotonergic agents.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase risk of serious side effects like respiratory depression.,Dizziness or drowsiness may occur; avoid driving or operating machinery until you know how the medication affects you.,Do not stop abruptly; taper dose under medical supervision to prevent withdrawal symptoms.,Common side effects include nausea, vomiting, constipation, dizziness, and headache.,Report symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heartbeat, fever, muscle stiffness) immediately.,Keep out of reach of children; misuse can cause overdose and death.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
"The combination of Propiverine, an anticholinergic agent used for overactive bladder, with Tapentadol, a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, can result in additive anticholinergic effects. This increases the risk of severe adverse effects such as urinary retention, constipation, dry mouth, blurred vision, and central nervous system depression. Elderly patients are especially susceptible to these effects, which may lead to falls, cognitive impairment, or anticholinergic toxicity."
"Lorazepam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tapentadol, an opioid analgesic, by enhancing GABAergic activity and reducing neurotransmitter release. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, profound hypotension, and increased risk of coma or death, particularly in elderly or debilitated patients. Clinical outcomes include heightened CNS depression, impaired psychomotor function, and potential for opioid-induced respiratory compromise when used concomitantly."
"Zonisamide, a sulfonamide anticonvulsant, potentiates the central nervous system (CNS) depressant effects of tapentadol, a mu-opioid agonist and norepinephrine reuptake inhibitor. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired psychomotor function, particularly when initiating or titrating either drug. Patients may experience increased risk of falls, cognitive impairment, and potentially life-threatening respiratory compromise."
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAPENTADOL vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
TAPENTADOL is a Opioid Agonist that works by Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAPENTADOL and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAPENTADOL is: Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TAPENTADOL and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE. Concurrent use of codeine and tapentadol results in additive central nervous system (CNS) depression, leading to increased risks of respiratory depression, sedation, coma, and death. Both drugs are mu-opioid receptor agonists, and tapentadol additionally inhibits norepinephrine reuptake, which does not mitigate the additive CNS effects. This combination should be avoided unless benefits outweigh risks, and patients must be closely monitored for signs of excessive CNS depression. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TAPENTADOL is classified as Category A/B. First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: . ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.